Cleveland Clinic Cancer Center/Fairview Hospital

Summary

Cleveland Clinic Cancer Center/Fairview Hospital is a medical facility located in Cleveland, Ohio. This center is recognized for care of Ovarian Cancer, Lung Cancer, Breast Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma and other specialties. Cleveland Clinic Cancer Center/Fairview Hospital is involved with conducting 283 clinical trials across 267 conditions. There are 34 research doctors associated with this hospital, such as Peter Rose, MD, David Peereboom, MD, Nathan A. Pennell, and Dale Shepard.

Top PIs

Clinical Trials running at Cleveland Clinic Cancer Center/Fairview Hospital

Ovarian Cancer

Prostate Cancer

Breast Cancer

Breast cancer

Pancreatic Cancer

Lung Cancer

Cancer

Prostate Adenocarcinoma

Endometrial Cancer

Uterine Cancer

Olaparib +/- Bevacizumab

for Ovarian Cancer

This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5'-diphosphoribose polymerase (PARP) enzyme inhibitor and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving olaparib for one year with or without bevacizumab may be effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Recruiting

2 awards

Phase 3

4 criteria

Targeted Therapy

for Solid Tumors

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally advanced) or have spread to other places in the body (advanced) and have progressed on at least one line of standard systemic therapy or have no standard treatment that has been shown to prolong overall survival may be candidates for these trials. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with some genetic changes or abnormalities (mutations) may benefit from treatment that targets that particular genetic mutation. ComboMATCH is designed to match patients to a treatment that may work to control their tumor and may help doctors plan better treatment for patients with locally advanced or advanced solid tumors.

Recruiting

1 award

Phase 2

17 criteria

Surgical Procedures

for Reducing Ovarian Cancer Risk

This clinical trial evaluates how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk reduction for women with BRCA1 mutations.

Recruiting

1 award

N/A